Your browser doesn't support javascript.
loading
Evaluation of the clinical efficacy of a water soluble formulation of tylvalosin in the control of enzootic pneumonia associated with Mycoplasma hyopneumoniae and Pasteurella multocida in pigs.
Lopez Rodriguez, Alfonso; Berge, Anna Catharina; Ramage, Cliff; Saltzman, Ryan; Domangue, Rickie J; Gnozzio, Mark J; Muller, Annika; Sierra, Pascale; Benchaoui, Hafid A.
Afiliação
  • Lopez Rodriguez A; ECO Animal Health Ltd., London, UK. Alfonso.Lopez@ecoanimalhealth.com.
  • Berge AC; Berge Veterinary Consulting BV, Vollezele, Belgium.
  • Ramage C; Moredun Scientific, Bush Loan, Penicuik, UK.
  • Saltzman R; Veterinary Resources Inc., Ames, IA, USA.
  • Domangue RJ; Rickie J. Domangue Statistical Consulting Services, Broadway, VA, USA.
  • Gnozzio MJ; ECO Animal Health Inc., Princeton, NJ, USA.
  • Muller A; Charles River Laboratories Edinburgh Ltd, Edinburgh, UK.
  • Sierra P; Parscivet, Gerstheim, France.
  • Benchaoui HA; ECO Animal Health Ltd., London, UK.
Porcine Health Manag ; 6(1): 39, 2020 Dec 04.
Article em En | MEDLINE | ID: mdl-33292620
BACKGROUND: The efficacy of a water soluble formulation of tylvalosin (Aivlosin® 625 mg/g granules) was evaluated in the treatment and metaphylaxis of Enzootic Pneumonia (EP) in pigs. In all four trials, pigs in the tylvalosin group were administered 10 mg tylvalosin/kg bodyweight in drinking water daily for 5 consecutive days (TVN). In a single-challenge study, pigs were inoculated with lung homogenate containing Mycoplasma hyopneumoniae. In a dual challenge study, pigs were sequentially inoculated with pure culture of M. hyopneumoniae and Pasteurella multocida. Efficacy was evaluated based on reduction of lung lesions compared to unmedicated control pigs (CTL). In two field studies at European commercial farms with confirmed outbreaks of EP, treatment efficacy in clinically affected fatteners was evaluated based on improved clinical conditions compared to pigs treated with tylosin at 10 mg/kg by injection for 3 consecutive days (TYL). In these field trials, healthy in contact pigs were enrolled for metaphylaxis efficacy evaluation based on reduction in incidence of new clinical cases of respiratory disease compared to unmedicated pigs (CTL). RESULTS: In the M. hyopneumoniae-only challenge study, pigs in TVN group had lower lung lesion scores than CTL (6.52 vs. 14.97; p <  0.001). In the dual challenge study with M. hyopneumoniae and P. multocida, pigs in TVN group had lower lung lesion scores than CTL (3.32 vs. 8.37; p <  0.01) and the recovery of both challenge bacteria from the lungs was lower in TVN compared with CTL group (p <  0.01). In field outbreaks of EP, multicentre analysis showed that 13 days after the start of medication, treatment success for TVN pigs was significantly better than for TYL pigs (80.0% vs 48.7% p = 0.03) and metaphylactic administration of TVN significantly reduced the incidence of new clinical cases (2.1% vs. 7.8%; p <  0.01) compared with unmedicated controls. CONCLUSIONS: Tylvalosin at 10 mg/kg daily for 5 days in drinking water was safe and effective in the treatment and metaphylaxis of EP in pigs associated with infections of M. hyopneumoniae either alone or in combination with P. multocida under both experimental challenge and field natural infection conditions.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Porcine Health Manag Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Porcine Health Manag Ano de publicação: 2020 Tipo de documento: Article